, Nov. 17, 2010
/PRNewswire/ -- Active electrode monitoring developed and manufactured by Boulder
-based Encision Inc. (Pink Sheets: ECIA), is the only monopolar energy technology proposed as a solution to eliminate visceral burns during Single Port Laparoscopy according to a recent study presentation. Encision is a medical device company owning patented surgical technology that is emerging as a standard of care in minimally invasive surgery.
The recommendations come as a result of a study reported by Dr. Basim Abu-Rafea at the 39th American Association of Gynecological Laparoscopists Global Congress of Minimally Invasive Gynecology. Dr. Abu-Rafea's paper, Single Port Laparoscopy and Monopolar Electrosurgery May Result in Visceral Burns, examined the effects of monopolar electrosurgery on various tissues/organs during simulated single port laparoscopic surgery in vitro and in vivo.
Dr. Abu-Rafea's conclusion was that "Monopolar electrosurgery during endoscopic surgery, compared with other energy sources, is associated with unique inherent risks and complications due to inadvertent direct coupling, capacitive coupling and insulation failure." Dr. Abu-Rafea continued, "These dangers become particularly important with the emergence of single port laparoscopy which requires close proximity and crossing of multiple intra-abdominal instruments."
Dr. Abu-Rafea also added, "During single port laparoscopy and use of monopolar energy, the proximity and crossing of instruments generates capacitive and/or direct coupled currents which may cause visceral burns. Proposed solutions include the use of active electrode monitoring when performing single port laparoscopy to prevent capacitive coupling and direct coupling or consider using other forms of energy such as harmonic or bipolar."
Jack Serino, Encision's president and CEO, responded in saying, "We are pleased that Encision's active electrode monitoring technology was again recognized as an important consideration to avoid inadvertent patient burns with the growing popularity of single port laparoscopy."
Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. The Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in our filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
Marcia McHaffie, Encision Inc., 303-444-2600, email@example.com
SOURCE Encision Inc.